Drug Profile
Research programme: CRTH2 receptor antagonists - Bristol-Myers Squibb
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Amira Pharmaceuticals
- Class
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypersensitivity; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergy in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA (PO)
- 07 Sep 2011 Amira Pharmaceuticals has been acquired by Bristol-Myers Squibb